Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma
Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and genetic level. MicroRNA (miRNA) deregulation was extensively studied in PTCs and FTCs. However, very limited information is available...
Saved in:
| Published in: | Thyroid (New York, N.Y.) Vol. 23; no. 11; p. 1383 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.11.2013
|
| Subjects: | |
| ISSN: | 1557-9077, 1557-9077 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and genetic level. MicroRNA (miRNA) deregulation was extensively studied in PTCs and FTCs. However, very limited information is available for FVPTC. The aim of this study was to assess miRNA expression in FVPTC with the most comprehensive miRNA array panel and to correlate it with the clinicopathological data.
Forty-four papillary thyroid carcinomas (17 FVPTC, 27 classic PTC) and eight normal thyroid tissue samples were analyzed for expression of 748 miRNAs using Human Microarray Assays on the ABI 7900 platform (Life Technologies, Carlsbad, CA). In addition, an independent set of 61 tumor and normal samples was studied for expression of novel miRNA markers detected in this study.
Overall, the miRNA expression profile demonstrated similar trends between FVPTC and classic PTC. Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p). However, the levels of miRNA expression were different between these tumor types and some miRNAs were uniquely dysregulated in FVPTC allowing separation of these tumors on the unsupervised hierarchical clustering analysis. Upregulation of novel miR-375 was confirmed in a large independent set of follicular cell derived neoplasms and benign nodules and demonstrated specific upregulation for PTC. Two miRNAs (miR-181a-2-3p, miR-99b-3p) were associated with an adverse outcome in FVPTC patients by a Kaplan-Meier (p < 0.05) and multivariate Cox regression analysis (p < 0.05).
Despite high similarity in miRNA expression between FVPTC and classic PTC, several miRNAs were uniquely expressed in each tumor type, supporting their histopathologic differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel marker of papillary thyroid carcinoma, and miR-181a-2-3p and miR-99b-3p can predict relapse-free survival in patients with FVPTC thus potentially providing important diagnostic and predictive value. |
|---|---|
| AbstractList | Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and genetic level. MicroRNA (miRNA) deregulation was extensively studied in PTCs and FTCs. However, very limited information is available for FVPTC. The aim of this study was to assess miRNA expression in FVPTC with the most comprehensive miRNA array panel and to correlate it with the clinicopathological data.BACKGROUNDFollicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and genetic level. MicroRNA (miRNA) deregulation was extensively studied in PTCs and FTCs. However, very limited information is available for FVPTC. The aim of this study was to assess miRNA expression in FVPTC with the most comprehensive miRNA array panel and to correlate it with the clinicopathological data.Forty-four papillary thyroid carcinomas (17 FVPTC, 27 classic PTC) and eight normal thyroid tissue samples were analyzed for expression of 748 miRNAs using Human Microarray Assays on the ABI 7900 platform (Life Technologies, Carlsbad, CA). In addition, an independent set of 61 tumor and normal samples was studied for expression of novel miRNA markers detected in this study.METHODSForty-four papillary thyroid carcinomas (17 FVPTC, 27 classic PTC) and eight normal thyroid tissue samples were analyzed for expression of 748 miRNAs using Human Microarray Assays on the ABI 7900 platform (Life Technologies, Carlsbad, CA). In addition, an independent set of 61 tumor and normal samples was studied for expression of novel miRNA markers detected in this study.Overall, the miRNA expression profile demonstrated similar trends between FVPTC and classic PTC. Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p). However, the levels of miRNA expression were different between these tumor types and some miRNAs were uniquely dysregulated in FVPTC allowing separation of these tumors on the unsupervised hierarchical clustering analysis. Upregulation of novel miR-375 was confirmed in a large independent set of follicular cell derived neoplasms and benign nodules and demonstrated specific upregulation for PTC. Two miRNAs (miR-181a-2-3p, miR-99b-3p) were associated with an adverse outcome in FVPTC patients by a Kaplan-Meier (p < 0.05) and multivariate Cox regression analysis (p < 0.05).RESULTSOverall, the miRNA expression profile demonstrated similar trends between FVPTC and classic PTC. Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p). However, the levels of miRNA expression were different between these tumor types and some miRNAs were uniquely dysregulated in FVPTC allowing separation of these tumors on the unsupervised hierarchical clustering analysis. Upregulation of novel miR-375 was confirmed in a large independent set of follicular cell derived neoplasms and benign nodules and demonstrated specific upregulation for PTC. Two miRNAs (miR-181a-2-3p, miR-99b-3p) were associated with an adverse outcome in FVPTC patients by a Kaplan-Meier (p < 0.05) and multivariate Cox regression analysis (p < 0.05).Despite high similarity in miRNA expression between FVPTC and classic PTC, several miRNAs were uniquely expressed in each tumor type, supporting their histopathologic differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel marker of papillary thyroid carcinoma, and miR-181a-2-3p and miR-99b-3p can predict relapse-free survival in patients with FVPTC thus potentially providing important diagnostic and predictive value.CONCLUSIONSDespite high similarity in miRNA expression between FVPTC and classic PTC, several miRNAs were uniquely expressed in each tumor type, supporting their histopathologic differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel marker of papillary thyroid carcinoma, and miR-181a-2-3p and miR-99b-3p can predict relapse-free survival in patients with FVPTC thus potentially providing important diagnostic and predictive value. Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical, morphological, and genetic level. MicroRNA (miRNA) deregulation was extensively studied in PTCs and FTCs. However, very limited information is available for FVPTC. The aim of this study was to assess miRNA expression in FVPTC with the most comprehensive miRNA array panel and to correlate it with the clinicopathological data. Forty-four papillary thyroid carcinomas (17 FVPTC, 27 classic PTC) and eight normal thyroid tissue samples were analyzed for expression of 748 miRNAs using Human Microarray Assays on the ABI 7900 platform (Life Technologies, Carlsbad, CA). In addition, an independent set of 61 tumor and normal samples was studied for expression of novel miRNA markers detected in this study. Overall, the miRNA expression profile demonstrated similar trends between FVPTC and classic PTC. Fourteen miRNAs were deregulated in FVPTC with a fold change of more than five (up/down), including miRNAs known to be upregulated in PTC (miR-146b-3p, -146-5p, -221, -222 and miR-222-5p) and novel miRNAs (miR-375, -551b, 181-2-3p, 99b-3p). However, the levels of miRNA expression were different between these tumor types and some miRNAs were uniquely dysregulated in FVPTC allowing separation of these tumors on the unsupervised hierarchical clustering analysis. Upregulation of novel miR-375 was confirmed in a large independent set of follicular cell derived neoplasms and benign nodules and demonstrated specific upregulation for PTC. Two miRNAs (miR-181a-2-3p, miR-99b-3p) were associated with an adverse outcome in FVPTC patients by a Kaplan-Meier (p < 0.05) and multivariate Cox regression analysis (p < 0.05). Despite high similarity in miRNA expression between FVPTC and classic PTC, several miRNAs were uniquely expressed in each tumor type, supporting their histopathologic differences. Highly upregulated miRNA identified in this study (miR-375) can serve as a novel marker of papillary thyroid carcinoma, and miR-181a-2-3p and miR-99b-3p can predict relapse-free survival in patients with FVPTC thus potentially providing important diagnostic and predictive value. |
| Author | Komminoth, Paul Moch, Holger Nikiforov, Yuri E Dettmer, Matthias Perren, Aurel Nikiforova, Marina N |
| Author_xml | – sequence: 1 givenname: Matthias surname: Dettmer fullname: Dettmer, Matthias organization: 1 Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania – sequence: 2 givenname: Aurel surname: Perren fullname: Perren, Aurel – sequence: 3 givenname: Holger surname: Moch fullname: Moch, Holger – sequence: 4 givenname: Paul surname: Komminoth fullname: Komminoth, Paul – sequence: 5 givenname: Yuri E surname: Nikiforov fullname: Nikiforov, Yuri E – sequence: 6 givenname: Marina N surname: Nikiforova fullname: Nikiforova, Marina N |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23427895$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUEtLxDAYDLLiPvToVXL00jVJm7Q5Losv8AGi55I2X9xom9SkXey_t-AKnmYYhmFmlmjmvAOEzilZU1LIq343rhmhbE1Eyo7QgnKeJ5Lk-ewfn6NljB-EUFHk6QmaszRjeSH5Ao1b33YBduCi3QN-tHXwL08bDN-TGqP1DnfBG9tY946tBtdbYyFi5_fQ4FaFTwgRW4eNbxpbD40KeK-CVa7H3uBOdbaZtBFPPYO3Gtcq1Nb5Vp2iY6OaCGcHXKG3m-vX7V3y8Hx7v908JDVPWZ9UBc9rmZK8IpkWFSeQaa5UJXWlqamV4dqotJKSasYlFRSUIqC5EFKDNoSt0OVv7rTja4DYl62NNUytHPghljTLZC5EQdLJenGwDlULuuyCnRaO5d9d7AdZY3Jz |
| CitedBy_id | crossref_primary_10_1002_ijc_31548 crossref_primary_10_1016_j_gene_2019_02_071 crossref_primary_10_3892_ijo_2015_3135 crossref_primary_10_3390_cancers10110443 crossref_primary_10_1097_MD_0000000000034998 crossref_primary_10_1002_ijc_29505 crossref_primary_10_1007_s12020_022_03185_7 crossref_primary_10_1155_2017_6496570 crossref_primary_10_1016_j_lfs_2021_119398 crossref_primary_10_1038_s41388_017_0088_9 crossref_primary_10_1097_PAP_0000000000000135 crossref_primary_10_5858_arpa_2014_0245_RA crossref_primary_10_1002_cncy_22012 crossref_primary_10_1155_2016_1427042 crossref_primary_10_1371_journal_pone_0170287 crossref_primary_10_1038_modpathol_2016_157 crossref_primary_10_2217_bmm_2019_0578 crossref_primary_10_1097_XCS_0000000000000541 crossref_primary_10_1111_cen_13972 crossref_primary_10_1186_s10020_020_00218_7 crossref_primary_10_1186_s12885_019_6154_7 crossref_primary_10_1111_his_13380 crossref_primary_10_1155_2022_7488708 crossref_primary_10_1007_s00292_019_0600_9 crossref_primary_10_1186_s12885_016_2240_2 crossref_primary_10_1210_jc_2013_2749 crossref_primary_10_3892_ijo_2014_2789 crossref_primary_10_1007_s12020_016_0866_0 crossref_primary_10_1016_j_tube_2013_08_004 crossref_primary_10_3389_fbioe_2021_687915 crossref_primary_10_1111_cyt_12555 crossref_primary_10_1007_s40137_013_0035_9 crossref_primary_10_3390_genes9010044 crossref_primary_10_1089_thy_2017_0127 crossref_primary_10_1002_hed_25866 crossref_primary_10_1158_0008_5472_CAN_14_3547 crossref_primary_10_3390_genes10100736 crossref_primary_10_3390_ijms20051114 crossref_primary_10_3892_or_2016_5113 crossref_primary_10_1089_thy_2015_0378 crossref_primary_10_1007_s00292_019_0613_4 crossref_primary_10_1186_s12879_015_0771_9 crossref_primary_10_1016_j_path_2018_05_002 crossref_primary_10_3892_etm_2019_7720 crossref_primary_10_1016_j_mce_2015_04_001 crossref_primary_10_1089_thy_2013_0640 crossref_primary_10_1007_s13277_016_5065_3 crossref_primary_10_1007_s12022_015_9363_x crossref_primary_10_1002_hed_24261 crossref_primary_10_1016_j_beem_2022_101656 crossref_primary_10_3892_ijo_2017_3960 crossref_primary_10_3390_cancers13184649 crossref_primary_10_1097_MD_0000000000013637 crossref_primary_10_3390_jmp2020008 crossref_primary_10_1002_jcb_27993 crossref_primary_10_3390_cancers11060885 crossref_primary_10_1002_jcla_23020 crossref_primary_10_1016_j_gene_2017_10_053 crossref_primary_10_1530_EJE_15_0647 crossref_primary_10_5858_arpa_2017_0174_RA crossref_primary_10_1016_j_jasc_2017_02_001 crossref_primary_10_1038_nrendo_2013_223 crossref_primary_10_1210_er_2017_00133 crossref_primary_10_1007_s13277_015_4611_8 crossref_primary_10_1016_j_bbadva_2022_100053 crossref_primary_10_1016_j_mam_2019_10_007 crossref_primary_10_1002_cjp2_38 crossref_primary_10_1089_ct_2015_27_180_182 crossref_primary_10_1089_gtmb_2015_0062 crossref_primary_10_1089_thy_2017_0382 crossref_primary_10_3390_cancers14225620 crossref_primary_10_1007_s40618_017_0735_6 crossref_primary_10_3389_fendo_2022_834456 crossref_primary_10_1016_j_cca_2018_06_012 crossref_primary_10_3892_mco_2015_540 crossref_primary_10_1016_j_jasc_2016_04_002 crossref_primary_10_1016_j_mce_2015_07_007 crossref_primary_10_1210_clinem_dgae034 crossref_primary_10_1016_j_canlet_2015_08_016 crossref_primary_10_3892_ol_2017_6028 crossref_primary_10_1186_s13148_018_0579_8 crossref_primary_10_1155_2020_3730657 crossref_primary_10_1089_thy_2015_0193 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1089/thy.2012.0632 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-9077 |
| ExternalDocumentID | 23427895 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 123 29Q 34G 39C 4.4 53G 5RE AAQQT ABBKN ABJNI ABOCM ACGFO ACGFS ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BNQNF CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD EMOBN F5P IAO IER IHR IM4 INH INR ITC MV1 NPM NQHIM O9- P2P RIG RML RMSOB UDS UE5 7X8 SCNPE |
| ID | FETCH-LOGICAL-c532t-b857c9307b04d6b50e4d5aab9dbd1fcaf5dfa3b991d259161eaa0ed5669dedf02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 104 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000326578800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-9077 |
| IngestDate | Fri Sep 05 12:08:04 EDT 2025 Mon Jul 21 05:50:43 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c532t-b857c9307b04d6b50e4d5aab9dbd1fcaf5dfa3b991d259161eaa0ed5669dedf02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23427895 |
| PQID | 1449766803 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1449766803 pubmed_primary_23427895 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-Nov 20131101 |
| PublicationDateYYYYMMDD | 2013-11-01 |
| PublicationDate_xml | – month: 11 year: 2013 text: 2013-Nov |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Thyroid (New York, N.Y.) |
| PublicationTitleAlternate | Thyroid |
| PublicationYear | 2013 |
| SSID | ssj0016873 |
| Score | 2.437302 |
| Snippet | Follicular variant of papillary thyroid carcinoma (FVPTC) shares features of papillary (PTC) and follicular (FTC) thyroid carcinomas on a clinical,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1383 |
| SubjectTerms | Adult Carcinoma - genetics Carcinoma - metabolism Carcinoma - mortality Carcinoma, Papillary Carcinoma, Papillary, Follicular - genetics Carcinoma, Papillary, Follicular - metabolism Carcinoma, Papillary, Follicular - mortality Disease-Free Survival Female Follow-Up Studies Gene Expression Profiling Gene Expression Regulation Humans Male MicroRNAs - metabolism Middle Aged Multivariate Analysis Oligonucleotide Array Sequence Analysis Predictive Value of Tests Proportional Hazards Models Thyroid Cancer, Papillary Thyroid Gland - metabolism Thyroid Neoplasms - genetics Thyroid Neoplasms - metabolism Thyroid Neoplasms - mortality Treatment Outcome |
| Title | Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23427895 https://www.proquest.com/docview/1449766803 |
| Volume | 23 |
| WOSCitedRecordID | wos000326578800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6Nt0kTfYkRSwebCmi0lvZZHYxYJOa1GL_vTNJSk-C4GVvgc3sZOabnS_zMXbjWR2CY0KhPSOFByoWCiAQXsdDfO9EoS11yN6egsEgHI3UsL5wK2pa5TImloEaspjuyFsI_DFzdkLHvZt-ClKNou5qLaGxzhouQhny6mC06iJ0wrLDjCkzEFgEBvWMTSdULbQC8brkLaZo-Tu6LLNMb_e_-9tjOzW-5N3KIfbZmkkP2Fa_7qAfsgUFgNy8V7x13ic-3vOgy813zYhNeSXjjSmNJ1BxiUzB02xuPviEyDx5wZOUW5rmXZJY-RzrbTwgnlk-1VOSMcoXHF89zxLgMYkVpdlEH7HX3sPL_aOo5RdE7LtyJqLQD2KFMSByPOhEvmM88LWOFETQtrG2PljtRggwAWsoRI5Ga8cA4kMFBqwjj9lGmqXmlHFFdQ-xtywg_JJaq1jLwAY0Lc-A126y66VRx-je1LPQqcm-ivHKrE12Up3MeFrN4RhLl3RClH_2h6fP2bYkIYvyL8IL1rD4cZtLthnPZ0mRX5V-g-tg2P8BnxjRAA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+MicroRNA+expression+profiling+identifies+novel+markers+in+follicular+variant+of+papillary+thyroid+carcinoma&rft.jtitle=Thyroid+%28New+York%2C+N.Y.%29&rft.au=Dettmer%2C+Matthias&rft.au=Perren%2C+Aurel&rft.au=Moch%2C+Holger&rft.au=Komminoth%2C+Paul&rft.date=2013-11-01&rft.issn=1557-9077&rft.eissn=1557-9077&rft.volume=23&rft.issue=11&rft.spage=1383&rft_id=info:doi/10.1089%2Fthy.2012.0632&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-9077&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-9077&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-9077&client=summon |